Cindy J. Rubin

Publications by Year

Research Areas

Peroxisome Proliferator-Activated Receptors, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Adipose Tissue and Metabolism, Diet and metabolism studies

Most-Cited Works

• → Obesity in Black Adolescent Girls: A Controlled Clinical Trial of Treatment by Diet, Behavior Modification, and Parental Support(1990)228 cited
• → Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy(2006)114 cited
• → Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes(2005)98 cited
• → Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea(2003)61 cited
• → Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered(2007)34 cited
• → Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride(2008)17 cited
• → Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor γ agonists(2008)16 cited
• → Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes(2009)15 cited
• → Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials(2000)14 cited
• → The long-term effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes(2000)3 cited